Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.
Frank Lin(The University of Sydney), David M. Thomas(New South Wales Department of Health), Christine E. Napier(University of Sydney), Rosemary Harrup(University of Tasmania), Michael P. Brown(South Australia Pathology), Peter Grimison(The University of Sydney), Damien Kee(Peter MacCallum Cancer Centre), Kenneth J. O’Byrne(Translational Research Institute), John P. Grady(Garvan Institute of Medical Research), Subotheni Thavaneswaran(The University of Sydney), Chee Khoon Lee(The University of Sydney), Jayesh Desai(Peter MacCallum Cancer Centre), Milita Zaheed(Prince of Wales Hospital), Michael Millward(The University of Western Australia), Mandy L. Ballinger(Garvan Institute of Medical Research), Maya Kansara(Garvan Institute of Medical Research), Michail Charakidis(Royal Adelaide Hospital), Paul Craft(Canberra Hospital), John Simes(The University of Sydney), Lucille Sebastian(Heidelberg University)
Cited by 2
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k